Real-World Data Shows Lecanemab Could Delay Alzheimer's Progression by 8.3 Years
Key Insights
Real-world data presented at the CTAD conference reveals lecanemab can delay progression from mild cognitive impairment to moderate Alzheimer's disease by 8.3 years in early-stage patients with low amyloid levels.
The findings significantly exceed previous clinical trial results that showed only 4-6 months delay, suggesting greater therapeutic potential than initially demonstrated.
An injectable version of lecanemab using an auto-injector was also presented, potentially making the treatment more accessible than the current IV drip administration.
Real-world data for the Alzheimer's drug lecanemab shows it could delay disease progression by more than eight years, far exceeding the modest benefits observed in clinical trials that led to its NHS rejection earlier this year.
The findings, presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego, demonstrate that long-term treatment with lecanemab could delay progression from mild cognitive impairment to moderate Alzheimer's disease by 8.3 years among patients with low levels of amyloid protein in the brain who started treatment at an early stage.
Significant Improvement Over Clinical Trial Results
The real-world data represents a dramatic improvement over previous clinical trial findings. In June, the National Institute for Health and Care Excellence (NICE) published final draft guidance stating that lecanemab and similar treatments had been shown to delay progression from mild to moderate Alzheimer's by only four to six months. NICE deemed the medicines could not be provided on the NHS because they were not good value for money and "only provide modest benefits at best."
The new data compared people given lecanemab treatment from an early stage of the disease with those who had not been treated, revealing substantially greater therapeutic potential than initially demonstrated in controlled clinical trials.
Enhanced Accessibility Through Injectable Formulation
Researchers also presented data about an injectable version of lecanemab, delivered using an auto-injector. This development could provide a more accessible way to administer the drug at home, eliminating the need for the current intravenous drip method. The injectable option appears to have similar risks of side effects to the existing IV version, potentially making treatment simpler and more accessible for patients.
Expert Commentary on Clinical Implications
Dr. Richard Oakley, associate director of research and innovation at Alzheimer's Society (search), commented on the significance of the findings: "For decades, people with Alzheimer's disease have been desperately waiting for treatments that slow disease progression. This new data on lecanemab's real world use outside of clinical trials is promising, as it indicates treating people earlier could provide more benefit."
However, Dr. Oakley emphasized the need for further understanding of practical implications: "We still need to understand what slowing of disease progression means for people living with Alzheimer's disease and their daily life, such as whether it will help them to stay independent and manage everyday tasks for longer."
Mechanism of Action and Drug Class
Lecanemab, manufactured by healthcare company Eisai and also known as Leqembi, belongs to a new class of targeted antibody drugs that slow down the early stages of Alzheimer's disease. These treatments represent a significant advancement in research because they target a known cause of the disease rather than merely treating symptoms.
The drug works by binding to amyloid, a protein that builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, lecanemab is designed to help clear the protein buildup and slow down cognitive decline. Another drug in this class, donanemab, was also approved for UK use but similarly rejected for NHS use.
Healthcare System Challenges
Dr. Oakley highlighted critical healthcare system barriers that must be addressed: "Breakthroughs like this will only make a difference if people are diagnosed early and accurately. Around one million people are living with dementia in the UK and more than a third don't have a diagnosis."
Despite lecanemab's current unavailability on the NHS, the research landscape remains active. "Hope is on the horizon with over 130 Alzheimer's disease drugs in clinical trials," Dr. Oakley noted, adding that "The UK Government must act now to improve dementia diagnosis and prepare the NHS for delivering these new treatments."
Disease Burden and Future Projections
According to Alzheimer's Society (search) data, Alzheimer's disease represents the most common form of dementia, with one in three people born in the UK today expected to develop dementia in their lifetime. By 2040, approximately 1.4 million people in the UK could be living with the condition.
Previous NHS England analysis suggested that bringing these new Alzheimer's drugs to the health service could cost £500 million to £1 billion per year, highlighting the economic challenges facing healthcare systems in implementing these breakthrough therapies.